News

The approvals introduced several new agents into a number of patient populations, including much-needed additions to some diseases lacking a large number of options.

Digital biomarkers offer promise to revolutionize the diagnosis and treatment of Alzheimer disease via our increasing ability to gather active and passive data.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team studied the interactions of ASMs and cenobamate.

In a NeurologyLive® Peer Exchange, a panel of migraine specialists discussed the novel therapies in development and those entering the market for the treatment of acute migraine.

Catch up on some of our most popular Peer Exchange panels with experts in the field, including discussions on epilepsy, migraine, multiple sclerosis, and more.

Guest Editor-in-Chief Karl Doghramji, MD, FAASM, DFAPA, discusses the recent steps forward that have been made in the care of patients with insomnia.

The director of the Mid-Atlantic Epilepsy and Sleep Center also noted how serious adverse effects from treatment can be detrimental to patients’ lives.

Here's what is coming soon to NeurologyLive.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss the neurologic symptoms associated with COVID-19.

The research scientist from the University of Texas Medical School discussed how he would like to use machine learning to aid in prediction and prophylactic treatment.

NeurologyLive compiled a number of interviews and conversations with leaders within the neurology community to discuss how the pandemic affected mental health, specifically at an in-hospital setting.

Neurology News Network for the week ending December 26, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 25, 2020.

Henry Ford Health System’s investment in advanced DBS technology and its commitment to multidisciplinary care has helped them become a leading treatment center for Parkinson disease and related movement disorders.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team worked to reduce deleterious ASM interactions.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss the resources and tools used to adapt to the COVID-19 pandemic.

The Merz Therapeutics product, marketed as Xeomin, is the first and only FDA-approved neuromodulator available for patients aged 2 years and older with chronic sialorrhea.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to discuss whether the COVID-19 pandemic forced clinicians to change treatment regimens or prescriptions.

The director of the Mid-Atlantic Epilepsy and Sleep Center also urged physicians to not give up on the search for effective AEDs for their patients.

The pandemic's impact stretches across all aspects of life, and has particularly concerning effects on the sleep of those working on the frontlines providing care of patients.

PTC Therapeutics announced the initiation of its third study of 2020 investigating vatiquinone.

Annual reviews of moderate to vigorous physical activity may help patients maintain adequate levels of activity after stroke.

NeurologyLive conducted a number of interviews and conversations with leaders within the neurology community to assess how the COVID-19 virus affected the pathology of neurologic disorders.

The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the findings of a phase 2 trial using ezogabine, a drug once FDA-approved to treat epilepsy, in patients with ALS.

Barry J. Byrne, MD, PhD, chief medical advisor, Muscular Dystrophy Association, calls for the prioritization of persons with neuromuscular diseases as early candidates for the COVID-19 vaccination implementation.

The phase 2b/3 study will enroll 160 patients with either familial or sporadic ALS with a primary end point in change from baseline on Revised Amyotrophic Lateral Sclerosis Functional Rating Scale score at 24 weeks.